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“When one admits that nothing is certain one must, 
I think, also admit that some things are more nearly 
certain than others”
Bertrand Russell
From “Am I An Atheist Or An Agnostic?”, 1947
English author, mathematician and philosopher 
(1872–1970)
Intuitively, early definite therapy should produce outcome
advantages. However, providing evidence to support this has
been limited. Several recent studies, discussed below, add
credence to this idea.
Early tracheostomy saves lives
The detrimental consequences of long-term oral (and nasal)
intubation in critically ill patients are well established. The
clinicians’ dilemma has always been one of deciding which
patients will benefit from tracheostomy and, crucially, when to
perform it. August saw the publication of a well designed trial
by Rumbak and colleagues [1] that addressed this issue in
severely ill patients. They randomly assigned 120 patients
who had required intubation for respiratory failure either to
early percutaneous tracheostomy (within 48 hours) or to
delayed tracheostomy (at 14–16 days). Inclusion criteria
were strictly defined; in particular, patients had to have an
Acute Physiology and Chronic Health Evaluation (APACHE)
II score above 25 and be projected to require ventilatory
support for longer than 14 days.
The results were dramatic. The authors demonstrated a
significant reduction in mortality (31.7% versus 61.7%),
incidence of ventilator-associated pneumonia (5% versus
25%), days spent on ventilatory support (8 versus 17) and
days sedated (3 versus 14) in the early tracheostomy group.
There was also a reduction in days spent in the intensive care
unit (ICU; 5 versus 16), but this was heavily influenced by the
ability to discharge patients to a weaning unit. The
Kaplan–Meier survival curve is striking, with the mortality
benefit emerging between days 17 and 22. The authors
hypothesized that the benefits of early tracheostomy are the
direct result of the reduction in ventilator-associated
pneumonia, which in turn resulted from cessation of sedation
at day 3, a reduction in time spent on ventilatory support and
the ability to change tracheostomy inner cannulae on a daily
basis, thereby preventing the accumulation of infected
secretions in the tube. The authors conceded that the
mortality in the delayed tracheostomy group was significantly
higher than that predicted by the APACHE II scores (61.7%
versus 50%) and caution against extrapolating these results
to a general ICU population. However, it would appear that
this study provides compelling evidence to consider early
tracheostomy in those patients who seem likely to require
prolonged ventilatory support.
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Abstract
Recent papers discussed include a positive trial of early tracheostomy, two negative studies of
targeted noninvasive ventilation, the long awaited results of the high versus low positive end-
expiratory pressure Acute Respiratory Distress Syndrome Clinical Trial Network trial and a simple but
illuminating study into prognostic markers and end-points of resucitation.
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Noninvasive ventilation fails to improve
outcome
Noninvasive ventilation (NIV) has become an established
intervention, with advocates/enthusiasts employing this
technique in a wide spectrum of patients with respiratory
failure. In the 1990s there was flurry of positive trials of NIV
versus intubation and intermittent positive pressure
ventilation (IPPV), especially as a primary intervention in
acute on chronic, hypercapnic respiratory failure. Since then,
however, there have been a series of negative trials as
investigators have extended the indications. Further negative
evidence has emerged from two recent studies.
In the first, Esteban and colleagues [2] undertook a
randomized, multicentre trial of NIV versus standard medical
therapy in patients who were electively extubated following at
least 48 hours of mechanical ventilation and who then
subsequently developed respiratory failure within the next
48 hours. Of 980 patients enrolled, 221 patients developed
respiratory failure and were then randomized to either NIV or
standard medical therapy. The primary outcome measures
were ICU mortality and need for reintubation. The trial was
stopped at an interim analysis because of a statistically
significant increase in mortality in the NIV group (25% versus
14%). The increased mortality came predominantly from the
subgroup of patients who required reintubation (38% versus
11%). There was no difference in the rates of reintubation,
but the interval between the development of respiratory
failure and reintubation was significantly longer in the NIV
group (12 versus 2.5 hours). The trial was well designed and,
although ICU mortality is arguably a poor outcome measure,
this trial suggests that NIV delays rather than prevents
reintubation and that reintubation is associated with a worse
outcome. Yet again, early definitive intervention appears to
offer patients the best chance of survival.
In the second trial, Squadrone and colleagues [3] compared a
trial of NIV in 64 chronic obstructive pulmonary disease patients
with acute severe hypercapnic respiratory failure (pH <7.25
and arterial carbon dioxide tension >70 torr) with historical
case control individuals who received IPPV. The authors
introduced their study by quoting recent survey findings that,
despite grade A evidence, NIV is under-utilized in chronic
obstructive pulmonary disease patients with acute
exacerbations. They conceded that there are limitations in their
study design but argued that their observations provide a useful
insight into the outcomes of such patients. Surprisingly, the pre-
ICU hospital stay averaged 5–6 days in both groups. NIV failed
in 62.5% of patients who went on to receive IPPV after an
average interval of 7.5 hours. The delay in intubation, in contrast
to the study by Esteban and coworkers, did not appear to have
an adverse effect on outcome. As one would expect, those
patients who avoided intubation had a better outcome. The
authors concluded that a trial of NIV should be undertaken in
such patients, albeit a high proportion will fail, because they
detected a trend toward better outcomes in the NIV cohort.
As with other novel ICU interventions, initial enthusiasm for
NIV appears to have resulted in overestimation of its efficacy.
It often fails, and such failure is associated with a worse
prognosis. However, when successful it offers significant
advantages. Predicting failure is near impossible and the
effects of delaying definitive intervention, at best, remain
unclear. Although widely speculative, it is tempting to ask
what effect early tracheostomy would have in the population
who fail NIV and appear likely to require more than
7–10 days of ventilatory support.
No to more PEEP
Once again the Acute Respiratory Distress Syndrome
Clinical Trial Network has produced some more data to help
in the quest for an optimal ventilatory strategy in the
treatment of acute respiratory distress syndrome. Brower and
coworkers [4] looked at the outcome effects of employing
high versus low positive end-expiratory pressure (PEEP)
levels in addition to a low tidal volume (6 ml/kg) strategy. The
trial was abandoned after the second interim analysis
because of no demonstrable benefit from higher PEEP levels.
The trial had recruited 549 patients who were randomly
assigned to receive predetermined combinations of PEEP
and fractional inspired oxygen. The higher level group
received a mean PEEP of 13.2 ± 3.5 cmH2O and the lower
level group 8.3 ± 3.2 cmH2O. The primary outcome measure
was in-hospital 60-day mortality. Not only was there no
difference in 60-day mortality, but also there was no
difference in ventilator-free days, ICU-free days, or organ
failure-free days.
Lactate clearance
From the emergency department in Detroit, home of early
goal-directed therapy [5], comes another simple and elegant
study of the art of resuscitation. Nguyen and colleagues [6]
conducted an observational study to investigate the utility of
estimating percentage lactate clearance in the first 6 hours of
sepsis treatment. Statistical analysis led the authors to
suggest that a 10% 6-hour lactate clearance is a useful
prognostic indicator. Although otherwise well matched by a
whole host of physiological measures, patients who failed to
clear more than 10% of their lactate had significantly worse
outcomes. Although not surprising, the authors suggested
that such a measure may prove useful as an end-point of
resuscitation.
Other talking points
In a statistically challenging paper, a multinational group of
intensivists investigated the link between diuretic use and
mortality in acute renal failure [7]. The conclusion appears to
be that there is no effect on mortality when diuretics are used
in the management of acute renal failure and that a trial to
determine efficacy is warranted.
The transmission of Creutzfeldt–Jakob disease in blood
products and via surgical instruments has been a major305
concern, especially in the UK. Three articles and an
accompanying editorial in the Lancet discuss the latest
research in the field and outline the benefits of a scientifically
guided, pragmatic approach to these issues [8].
Finally, we were surprised to read an editorial in JAMA in
which the author argued the case for open access visiting in
ICUs [9]. Open access has been the policy on all units in
both the UK and Australia in which we have worked, and we
were unaware that the issue was even considered
contentious. With that report coming from the USA, the
cultural divide in critical care is all the more surprising. To all
those practising in units with restricted visiting, we would
encourage you to read and discuss this editorial.
Conclusion
Let the friends and family in, consider lactate clearance and
early tracheostomy but use NIV with care.
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